153 related articles for article (PubMed ID: 18222602)
1. Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Brandau S
Eur Urol; 2008 Sep; 54(3):629-30. PubMed ID: 18222602
[No Abstract] [Full Text] [Related]
2. Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
Dovedi SJ; Kirby JA; Davies BR; Leung H; Kelly JD
Eur Urol; 2008 Sep; 54(3):621-30. PubMed ID: 18222600
[TBL] [Abstract][Full Text] [Related]
3. Predicting bacillus Calmette-Guerin immunotherapy effectiveness.
Griffith TS
J Urol; 2007 Dec; 178(6):2247-8. PubMed ID: 17936825
[No Abstract] [Full Text] [Related]
4. Immunotherapy for the treatment of superficial and infiltrative bladder carcinoma.
Cockett AT; Merguerian PA; di Sant'Agnese PA; Wheeless LL
Prog Clin Biol Res; 1989; 303():455-62. PubMed ID: 2675003
[No Abstract] [Full Text] [Related]
5. Editorial: urothelial tumors--liberal applications of conservative approaches.
Droller MJ
J Urol; 2003 Mar; 169(3):936-7. PubMed ID: 12576816
[No Abstract] [Full Text] [Related]
6. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
Leibovici D; Zisman A; Lindner A
Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074
[No Abstract] [Full Text] [Related]
7. Editorial comment on: Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
de Reijke TM
Eur Urol; 2009 Jun; 55(6):1395-6. PubMed ID: 19193488
[No Abstract] [Full Text] [Related]
8. Mathematical model of BCG immunotherapy in superficial bladder cancer.
Bunimovich-Mendrazitsky S; Shochat E; Stone L
Bull Math Biol; 2007 Aug; 69(6):1847-70. PubMed ID: 17457655
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a gene therapy treatment for transitional cell carcinoma.
Zhang X; Godbey WT
Cancer Gene Ther; 2011 Jan; 18(1):34-41. PubMed ID: 20847752
[TBL] [Abstract][Full Text] [Related]
10. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.
Soloway MS; Lee CT; Steinberg GD; Ghandi AA; Jewett MA
Urol Oncol; 2007; 25(4):338-40. PubMed ID: 17628304
[TBL] [Abstract][Full Text] [Related]
11. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
[No Abstract] [Full Text] [Related]
12. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
[No Abstract] [Full Text] [Related]
13. The optimal management of T1G3 bladder cancer.
Emiliozzi P; Pansadoro A; Pansadoro V
BJU Int; 2008 Nov; 102(9 Pt B):1265-73. PubMed ID: 19035891
[No Abstract] [Full Text] [Related]
14. Acute granulomatous tubulointerstitial nephritis caused by intravesical BCG.
Kennedy SE; Shrikanth S; Charlesworth JA
Nephrol Dial Transplant; 2006 May; 21(5):1427-9. PubMed ID: 16455675
[No Abstract] [Full Text] [Related]
15. Mathematical model of pulsed immunotherapy for superficial bladder cancer.
Bunimovich-Mendrazitsky S; Byrne H; Stone L
Bull Math Biol; 2008 Oct; 70(7):2055-76. PubMed ID: 18716846
[TBL] [Abstract][Full Text] [Related]
16. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
17. Antitumoral effect of celecoxib in hepatocellular carcinoma.
Malka D; Pacault V; De Baere T; Ducreux M; Boige V
J Clin Oncol; 2005 Jul; 23(21):4805-6. PubMed ID: 16034068
[No Abstract] [Full Text] [Related]
18. Vitamin E analog, alpha-tocopherol ether-linked acetic acid analog, alone and in combination with celecoxib, reduces multiplicity of ultraviolet-induced skin cancers in mice.
Riedel SB; Fischer SM; Sanders BG; Kline K
Anticancer Drugs; 2008 Feb; 19(2):175-81. PubMed ID: 18176114
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy.
Esuvaranathan K; Alexandroff AB; McIntyre M; Jackson AM; Prescott S; Chisholm GD; James K
J Urol; 1995 Aug; 154(2 Pt 1):572-5. PubMed ID: 7609139
[TBL] [Abstract][Full Text] [Related]
20. Did targeted therapy fail cyclooxygenase too?
Csiki I; Johnson DH
J Clin Oncol; 2006 Oct; 24(30):4798-800. PubMed ID: 17050864
[No Abstract] [Full Text] [Related]
[Next] [New Search]
